Articles

Felicita Andreotti, Italy; Christiaan J M Vrints, Belgium

Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare and life-threatening blood disorder characterized by severe deficiency of the enzyme ADAMTS13, leading to the formation of microthrombi in small blood vessels. This condition requires prompt and effective treatment to prevent serious complications.

Caplacizumab is an innovative nanobody^® and cornerstone in the treatment of iTTP.¹ This article delves into real-world data from Belgian hospitals on the use of caplacizumab, highlighting its efficacy, safety, and impact on patient outcomes.²

This infographic summarizes survey data^* about the impact that families in Belgium and the Netherlands have felt when being diagnosed with autoimmune Type 1 Diabetes (T1D).

Systematic early detection of autoimmune Type 1 Diabetes might be a new way to avoid acute and chronic complications of the condition.^1-5 This new approach may play a role as a revolutionary shift, helping to shape the future of Type 1 Diabetes management.²

Start to think differently about Type 1 Diabetes by considering the pre-symptomatic stages of the condition and how it affects people of all ages and their families.

Written by Anna Ekman, Medical Lead North Europe at Sanofi

Can you find the right diagnosis for David?

Can you find the right diagnosis for Emily?

This patient has Thrombotic Thrombocytopenic Purpura (TTP).

Can you find the right diagnosis for Sarah?

This patient has Thrombotic Thrombocytopenic Purpura (TTP).